Stock futures point to an ugly start for Wall Street on Monday, Broadcom set to raise its offer for Qualcomm, the Philadelphia Eagles beat the New England Patriots in Super Bowl LII.
With Baker Hughes, General Electric is stuck between a rock and a hard place. The company may miss out by shopping its majority stake when compared to selling off pieces of the business, but the most attractive assets are also the most valuable at this point in the cycle.
Gilead Sciences' Kite will make a futuristic one-time dose that claims to cure a rare blood cancer in a few weeks. It costs about a third of a million dollars.
This energy trade is sending a major buy signal for the first time in 2017.